BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3332Biotechnology
$10.41 −$0.15 (-1.42%)
Pre-market · Oct 8, 8:30 am ET · After hours $10.52 +1.06%
Open$10.25
Prev close$10.56
Day range$10.25 – $10.65
Volume1.16M
Market cap$875.70M
P/E (TTM)–
Dividend yield–

CRVS Stock News

Headlines matching Corvus Pharmaceuticals or the CRVS ticker, most recent first.

  • Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28Market news · 7 Aug 2026 · Direct mention
  • Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30Market news · 12 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27Market news · 10 Aug 2026 · Direct mention
  • Corvus Pharmaceuticals (CRVS.US) will release its earnings report after market close on August 6.Market news · 1 Aug 2026 · Direct mention
  • Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33Market news · 8 May 2026 · Direct mention
  • A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40Market news · 15 May 2026 · Direct mention
  • Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40Market news · 12 May 2026 · Direct mention
  • Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40Market news · 17 Apr 2026 · Direct mention
  • Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $33 PositiveMarket news · 13 Mar 2026 · Direct mention
  • Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $30 PositiveMarket news · 29 Jan 2026 · Direct mention
  • Jefferies Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $42 PositiveMarket news · 23 Jan 2026 · Direct mention
  • Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $28 PositiveMarket news · 21 Jan 2026 · Direct mention
  • H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $27 PositiveMarket news · 21 Jan 2026 · Direct mention
  • Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $32 PositiveMarket news · 21 Jan 2026 · Direct mention
  • Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $20 PositiveMarket news · 21 Jan 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on CRVS.

Leave a comment

Scroll to Top